放疗前使用乐伐替尼诱导化疗治疗局部未切除胸腺癌：病例报告。

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2024-11-08 DOI:10.2169/internalmedicine.4383-24

Shodai Fujimoto, Naoko Katsurada, Rie Sasaki, Takeaki Ishihara, Daisuke Hazama, Masatsugu Yamamoto, Motoko Tachihara

{"title":"放疗前使用乐伐替尼诱导化疗治疗局部未切除胸腺癌：病例报告。","authors":"Shodai Fujimoto, Naoko Katsurada, Rie Sasaki, Takeaki Ishihara, Daisuke Hazama, Masatsugu Yamamoto, Motoko Tachihara","doi":"10.2169/internalmedicine.4383-24","DOIUrl":null,"url":null,"abstract":"Thymic carcinoma (TC) is a rare malignancy with limited treatment options. Lenvatinib, a novel multitarget kinase inhibitor, has recently been used to treat advanced or metastatic thymic carcinoma that cannot be surgically removed. To date, there have been no reports of lenvatinib being used as induction chemotherapy prior to radiotherapy in cases of localized, unresectable thymic carcinoma. We herein report an 85-year-old Japanese woman with localized unresectable thymic carcinoma who was treated with lenvatinib as induction chemotherapy before undergoing radiotherapy. Our findings suggest that lenvatinib may be a viable option for induction chemotherapy in similar clinical scenarios.","PeriodicalId":13719,"journal":{"name":"Internal Medicine","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Localized Unresectable Thymic Carcinoma Treated with Induction Chemotherapy with Lenvatinib before Radiotherapy: A Case Report.\",\"authors\":\"Shodai Fujimoto, Naoko Katsurada, Rie Sasaki, Takeaki Ishihara, Daisuke Hazama, Masatsugu Yamamoto, Motoko Tachihara\",\"doi\":\"10.2169/internalmedicine.4383-24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Thymic carcinoma (TC) is a rare malignancy with limited treatment options. Lenvatinib, a novel multitarget kinase inhibitor, has recently been used to treat advanced or metastatic thymic carcinoma that cannot be surgically removed. To date, there have been no reports of lenvatinib being used as induction chemotherapy prior to radiotherapy in cases of localized, unresectable thymic carcinoma. We herein report an 85-year-old Japanese woman with localized unresectable thymic carcinoma who was treated with lenvatinib as induction chemotherapy before undergoing radiotherapy. Our findings suggest that lenvatinib may be a viable option for induction chemotherapy in similar clinical scenarios.\",\"PeriodicalId\":13719,\"journal\":{\"name\":\"Internal Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2169/internalmedicine.4383-24\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2169/internalmedicine.4383-24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

胸腺癌（TC）是一种罕见的恶性肿瘤，治疗方案有限。来伐替尼是一种新型多靶点激酶抑制剂，最近被用于治疗无法手术切除的晚期或转移性胸腺癌。迄今为止，还没有关于来伐替尼在局部无法切除的胸腺癌放疗前用作诱导化疗的报道。我们在此报告了一名85岁的日本女性患者，她患有局部不可切除的胸腺癌，在接受放疗前使用了来伐替尼作为诱导化疗。我们的研究结果表明，在类似的临床情况下，来伐替尼可能是一种可行的诱导化疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Localized Unresectable Thymic Carcinoma Treated with Induction Chemotherapy with Lenvatinib before Radiotherapy: A Case Report.

Thymic carcinoma (TC) is a rare malignancy with limited treatment options. Lenvatinib, a novel multitarget kinase inhibitor, has recently been used to treat advanced or metastatic thymic carcinoma that cannot be surgically removed. To date, there have been no reports of lenvatinib being used as induction chemotherapy prior to radiotherapy in cases of localized, unresectable thymic carcinoma. We herein report an 85-year-old Japanese woman with localized unresectable thymic carcinoma who was treated with lenvatinib as induction chemotherapy before undergoing radiotherapy. Our findings suggest that lenvatinib may be a viable option for induction chemotherapy in similar clinical scenarios.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.